Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAarif AhsanACAlfred ChungJMJohn McKay

Discussion

Loading...

Member takes

Overview

Phase 1 study shows etentamig monotherapy improves M-protein detection in relapsed multiple myeloma, indicating potential as a biomarker.

Key Points

  • To evaluate the effectiveness of etentamig monotherapy on M-protein detection and residual disease in relapsed or refractory multiple myeloma patients.
  • Performed clonotypic peptide mass spectrometry on serum samples from MRD evaluable patients
  • Analyzed bone marrow MRD negativity using next generation sequencing
  • Measured serum M-protein levels and patient responses over time after etentamig treatment
  • 80% of patients had at least one clonotypic peptide identified prior to treatment
  • Significant decline in MS M-protein levels correlated with better IMWG responses
  • Lowest detectable M-protein levels were found to be 44 mg/dL with quantitation limits at 10 mg/dL
  • MRD-negative patients demonstrated a deeper reduction in M-protein levels compared to MRD-positive patients

Cite This Study

Ahsan et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe0https://doi.org/10.1182/blood-2025-5813
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses2025
  2. 2Clonotypic peptide mass spectrometry to monitor m-protein reduction in patients with relapsed/refractory multiple myeloma from ikema Study2025
  3. 3B-241 Next-generation monitoring: M-inSightclinical application in multiple myeloma2024
  4. 4Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis2025 · 3 citations
  5. 5Data from Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)2024